Pensioenfonds Rail & OV purchased a new position in shares of Eli Lilly and Company (NYSE:LLY – Free Report) in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 6,665 shares of the company’s stock, valued at approximately $7,713,000. Eli Lilly and Company comprises about 2.0% of Pensioenfonds Rail & OV’s portfolio, making the stock its 16th biggest position.
Several other hedge funds also recently made changes to their positions in the business. IFG Advisory LLC raised its holdings in Eli Lilly and Company by 4.4% during the third quarter. IFG Advisory LLC now owns 4,522 shares of the company’s stock worth $5,232,000 after acquiring an additional 189 shares in the last quarter. Trillium Asset Management LLC boosted its position in Eli Lilly and Company by 1,302.8% during the third quarter. Trillium Asset Management LLC now owns 5,036 shares of the company’s stock valued at $5,831,000 after purchasing an additional 4,677 shares during the last quarter. Phoenix Financial Ltd. boosted its position in Eli Lilly and Company by 0.3% during the third quarter. Phoenix Financial Ltd. now owns 97,306 shares of the company’s stock valued at $105,333,000 after purchasing an additional 287 shares during the last quarter. Hansen & Associates Financial Group Inc. increased its position in shares of Eli Lilly and Company by 16.8% during the 3rd quarter. Hansen & Associates Financial Group Inc. now owns 1,104 shares of the company’s stock worth $1,292,000 after purchasing an additional 159 shares during the last quarter. Finally, California First Leasing Corp acquired a new position in shares of Eli Lilly and Company during the 3rd quarter worth approximately $2,968,000. 82.53% of the stock is owned by institutional investors.
Insider Buying and Selling at Eli Lilly and Company
In other Eli Lilly and Company news, EVP Patrik Jonsson sold 6,500 shares of the company’s stock in a transaction on Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the transaction, the executive vice president directly owned 54,147 shares in the company, valued at $63,628,139.70. The trade was a 10.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of the stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $1,402.52, for a total transaction of $7,012,600.00. Following the completion of the transaction, the executive vice president directly owned 4,137 shares in the company, valued at $5,802,225.24. The trade was a 54.72% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.14% of the company’s stock.
Wall Street Analysts Forecast Growth
LLY has been the topic of a number of analyst reports. Leerink Partners upped their price objective on Eli Lilly and Company from $1,309.00 to $1,316.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 21st. Weiss Ratings cut shares of Eli Lilly and Company from a “buy (b+)” rating to a “buy (b)” rating in a research note on Friday, October 30th. Berenberg Bank upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating and set a $1,400.00 target price on the stock in a report on Tuesday, September 15th. Truist Financial reaffirmed a “buy” rating and set a $1,612.00 price target (up from $1,376.00) on shares of Eli Lilly and Company in a research report on Friday, October 30th. Finally, Morgan Stanley increased their price target on shares of Eli Lilly and Company from $1,430.00 to $1,596.00 and gave the company an “overweight” rating in a research note on Friday, October 30th. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Eli Lilly and Company has an average rating of “Moderate Buy” and a consensus price target of $1,416.64.
Check Out Our Latest Research Report on Eli Lilly and Company
Latest Eli Lilly and Company News
These are some of the LLY news items that stood out recently:
- Positive Sentiment: Lilly broke ground on a $3.5 billion Pennsylvania manufacturing facility intended to make next-generation obesity medicines, including investigational retatrutide. The project supports the company’s broader production expansion, although the site is not expected to begin operations until 2031. Lilly announces Pennsylvania manufacturing facility
- Positive Sentiment: Hims & Hers will offer Lilly’s FDA-approved Zepbound and Foundayo, potentially extending patient reach through another care platform. Separately, exchange-traded funds were reported to have added to their Lilly holdings, signaling investor demand. Hims partners with Lilly to offer weight-loss drugs
- Negative Sentiment: China Merchants Securities downgraded Lilly from “buy” to “hold,” providing a cautionary view amid the positive product and capacity news. China Merchants Securities stock recommendations
Eli Lilly and Company Stock Performance
Eli Lilly and Company stock traded up $16.77 during midday trading on Friday, reaching $1,444.05. 2,080,606 shares of the company’s stock were exchanged, compared to its average volume of 3,003,279. The stock’s 50-day simple moving average is $1,242.25 and its 200 day simple moving average is $1,110.30. The firm has a market cap of $1.36 trillion, a price-to-earnings ratio of 46.87, a P/E/G ratio of 1.71 and a beta of 0.40. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.00 and a current ratio of 1.39. Eli Lilly and Company has a 52 week low of $850.51 and a 52 week high of $1,460.00.
Eli Lilly and Company (NYSE:LLY – Get Free Report) last released its quarterly earnings data on Thursday, October 29th. The company reported $7.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.71 by $1.77. Eli Lilly and Company had a return on equity of 86.76% and a net margin of 31.90%. The firm had revenue of $24.40 billion for the quarter, compared to analyst estimates of $22.58 billion. During the same quarter in the prior year, the company earned $7.02 earnings per share. The business’s revenue for the quarter was up 38.6% compared to the same quarter last year. On average, analysts expect that Eli Lilly and Company will post 35.70 earnings per share for the current fiscal year.
Eli Lilly and Company Announces Dividend
The firm also recently declared a quarterly dividend, which will be paid on Thursday, December 10th. Shareholders of record on Friday, November 13th will be issued a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, November 13th. This represents a $6.92 annualized dividend and a yield of 0.5%. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 22.46%.
Eli Lilly and Company Profile
Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management. The company’s medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.
Further Reading
- Five stocks we like better than Eli Lilly and Company
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.
